PT  - JOURNAL ARTICLE
AU  - YUTARO KUBOTA
AU  - QINGHONG HAN
AU  - SEI MORINAGA
AU  - TAKUYA TSUNODA
AU  - ROBERT M. HOFFMAN
TI  - Rapid Reduction of CEA and Stable Metastasis in an <em>NRAS</em>-mutant Rectal-Cancer Patient Treated With FOLFIRI and Bevacizumab Combined With Oral Recombinant Methioninase and a Low-Methionine Diet Upon Metastatic Recurrence After FOLFIRI and Bevacizumab Treatment Alone
AID  - 10.21873/invivo.13310
DP  - 2023 Sep 01
TA  - In Vivo
PG  - 2134--2138
VI  - 37
IP  - 5
4099  - http://iv.iiarjournals.org/content/37/5/2134.short
4100  - http://iv.iiarjournals.org/content/37/5/2134.full
SO  - In Vivo2023 Sep 01; 37
AB  - Background/Aim: The choice of chemotherapy agents for RAS-mutant colorectal cancer is limited, and prognosis is poor compared to RAS-wild-type colorectal cancer. The purpose of the present study was to evaluate the effectiveness of methionine restriction combined with chemotherapy in a patient with NRAS-mutant rectal cancer. Patients and Methods: A 59-year-old female was diagnosed with lung-metastatic recurrence of NRAS-mutant rectal cancer two and a half years after resection of the primary tumor. She started chemotherapy, which consisted of fluorouracil, irinotecan (FOLFIRI), and bevacizumab, in October 2020. Eight months later, stereotactic body radiation therapy (SBRT) was performed to treat the lung metastases. She stopped chemotherapy at this point and had blood tests and computed tomography (CT) scans regularly. Her CEA level increased to 139.91 ng/ml and her lung metastasis became larger by September 2022. Therefore, she was reintroduced to FOLFIRI and bevacizumab in October 2022, and also started a low-methionine diet and oral recombinant methioninase (o-rMETase) as a supplement. Results: After starting the combination therapy with o-rMETase, a low-methionine diet, FOLFIRI, and bevacizumab, blood CEA levels very rapidly decreased and were almost within the normal limits five months later. CT findings showed the lung metastasis did not grow. Conclusion: Methionine restriction comprising o-rMETase and a low-methionine diet combined with first-line chemotherapy was effective in a patient with NRAS-mutant rectal cancer in which metastasis had re-occurred after first-line chemotherapy alone.